Table 1.
Characteristics of participants according to quartiles of plasma sTREM2
| Characteristics * | sTREM2, pg/mL | p trend | |||
|---|---|---|---|---|---|
| < 247.45 | 247.45–401.27 | 401.27–651.60 | ≥ 651.60 | ||
| No. of patients | 822 | 820 | 822 | 821 | |
| Demographic features | |||||
| Age, y | 57.0 (50.0–64.0) | 60.0 (53.0–68.0) | 62.0 (56.0–71.0) | 68.0 (59.0–74.0) | < 0.001 |
| Male sex, n (%) | 613 (74.6) | 551 (67.2) | 491 (59.7) | 443 (54.0) | < 0.001 |
| Current cigarette smoking, n (%) | 354 (43.1) | 310 (37.8) | 289 (35.2) | 253 (30.8) | < 0.001 |
| Current alcohol drinking, n (%) | 302 (36.7) | 288 (35.1) | 227 (27.6) | 192 (23.4) | < 0.001 |
| Clinical features | |||||
| Time from onset to randomization, h | 10.0 (5.00–24.0) | 12.0 (5.0–24.0) | 10.0 (4.0–24.0) | 10.0 (4.0–24.0) | 0.12 |
| Admission systolic BP, mm Hg | 161.3 (152.0–178.7) | 163.3 (152.0–178.7) | 161.3 (152.0–176.0) | 162.0 (152.0–178.7) | 0.63 |
| Admission diastolic BP, mm Hg | 98.7 (90.0–101.3) | 98.7 (90.0–101.3) | 98.7 (90.0–100.7) | 94.7 (88.7–100.0) | < 0.001 |
| Triglyceride, mmol/L | 1.4 (1.0–2.0) | 1.6 (1.0–2.3) | 1.5 (1.0–2.3) | 1.5 (1.0–2.2) | 0.78 |
| Total cholesterol, mmol/L | 4.8 (4.2–5.5) | 5.0 (4.3–5.7) | 5.1 (4.3–5.7) | 5.1 (4.4–5.8) | < 0.001 |
| LDL-cholesterol, mmol/L | 2.8 (2.2–3.4) | 2.9 (2.3–3.5) | 2.9 (2.3–3.5) | 2.9 (2.3–3.6) | 0.009 |
| HDL-cholesterol, mmol/L | 1.2 (1.0–1.5) | 1.2 (1.0–1.5) | 1.2 (1.0–1.5) | 1.3 (1.0–1.6) | < 0.001 |
| Fasting plasma glucose, mmol/L | 5.8 (5.1–7.2) | 5.8 (5.1–7.4) | 5.8 (5.2–7.2) | 5.8 (5.0–7.1) | 0.68 |
| Admission NIHSS score | 4.0 (2.0–8.0) | 4.0 (2.0–7.0) | 4.0 (3.0–7.0) | 5.0 (3.0–8.0) | 0.01 |
| High-sensitivity C-reactive protein, mg/L | 1.7 (0.6–4.1) | 1.8 (0.8–4.9) | 1.9 (0.7–4.5) | 2.3 (0.8–5.5) | 0.38 |
| Medical history, n (%) | |||||
| Hypertension | 658 (80.0) | 648 (79.0) | 643 (78.2) | 633 (77.1) | 0.13 |
| Hyperlipidemia | 44 (5.4) | 65 (7.9) | 65 (7.9) | 63 (7.7) | 0.09 |
| Diabetes mellitus | 140 (17.0) | 158 (19.3) | 148 (18.0) | 136 (16.6) | 0.66 |
| Coronary heart disease | 58 ( 7.1) | 66 ( 8.0) | 97 (11.8) | 117 (14.3) | < 0.001 |
| Family history of stroke, n (%) | 185 (22.5) | 163 (19.9) | 135 (16.4) | 132 (16.1) | < 0.001 |
| Medication use history, n (%) | |||||
| Antihypertensive medications | 372 (45.3) | 408 (49.8) | 403 (49.0) | 431 (52.5) | 0.007 |
| Lipid-lowering medications | 17 (2.1) | 29 (3.5) | 34 (4.1) | 32 (3.9) | 0.03 |
| Ischemic stroke subtype, n (%) | |||||
| Thrombotic | 644 (78.4) | 648 (79.0) | 628 (76.4) | 599 (73.0) | 0.004 |
| Embolic | 18 (2.2) | 38 (4.6) | 35 (4.3) | 65 (7.9) | < 0.001 |
| Lacunar | 160 (19.5) | 134 (16.3) | 159 (19.3) | 157 (19.1) | 0.75 |
| Randomized treatment, n (%) | 404 (49.1) | 420 (51.2) | 400 (48.7) | 423 (51.5) | 0.56 |
| Galectin-3, ng/ml | 7.5 (5.2–10.1) | 8.5 (5.9–11.3) | 8.6 (6.3–11.8) | 9.8 (6.5–13.9) | < 0.001 |
sTREM2 soluble triggering receptor expressed on myeloid cells 2, BP blood pressure, LDL low-density lipoprotein, HDL high-density lipoprotein, NIHSS NIH Stroke Scale
*Continuous variables are expressed as mean ± SD or median (interquartile range). Categorical variables are expressed as frequency (%)